{"filing":{"accession_number":"0001437749-26-027667","cik":"0000811641","ticker":"ICCC","company_name":"IMMUCELL CORP /DE/","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"iccc20260808_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/811641/000143774926027667/iccc20260808_8k.htm"},"events":[{"id":27608,"run_id":25173,"accession_number":"0001437749-26-027667","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"ImmuCell issued a press release on August 13, 2026 announcing unaudited financial results for the quarter ended June 30, 2026. The disclosure includes condensed statements of income, balance sheet data, and cash flow data for the period, with management commentary on revenue growth (11.5%), net income ($1.8 million), and operational performance. This is a standard quarterly earnings release attached as Exhibit 99.1, filed under Item 2.02 (Results of Operations and Financial Condition).","company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29199,"accession_number":"0001437749-26-027667","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"ImmuCell issued a press release on August 13, 2026 announcing unaudited financial results for the quarter ended June 30, 2026. The disclosure includes condensed statements of income, balance sheet data, and cash flow data for the period, with management commentary on revenue growth (11.5%), net income ($1.8 million), and operational performance. This is a standard quarterly earnings release attached as Exhibit 99.1, filed under Item 2.02 (Results of Operations and Financial Condition).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:03:23.155305+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29199,"accession_number":"0001437749-26-027667","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"ImmuCell issued a press release on August 13, 2026 announcing unaudited financial results for the quarter ended June 30, 2026. The disclosure includes condensed statements of income, balance sheet data, and cash flow data for the period, with management commentary on revenue growth (11.5%), net income ($1.8 million), and operational performance. This is a standard quarterly earnings release attached as Exhibit 99.1, filed under Item 2.02 (Results of Operations and Financial Condition).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:03:23.155305+00:00","company_name":"IMMUCELL CORP /DE/","ticker":"ICCC","filing_date":"2026-08-13"}]}